MX2007004247A - Agentes de aglutinacion especifica a angiopoyetina-2. - Google Patents

Agentes de aglutinacion especifica a angiopoyetina-2.

Info

Publication number
MX2007004247A
MX2007004247A MX2007004247A MX2007004247A MX2007004247A MX 2007004247 A MX2007004247 A MX 2007004247A MX 2007004247 A MX2007004247 A MX 2007004247A MX 2007004247 A MX2007004247 A MX 2007004247A MX 2007004247 A MX2007004247 A MX 2007004247A
Authority
MX
Mexico
Prior art keywords
angiopoietin
specific binding
binding agents
antibodies
disclosed
Prior art date
Application number
MX2007004247A
Other languages
English (en)
Spanish (es)
Inventor
Jonathan Daniel Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2007004247A publication Critical patent/MX2007004247A/es

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007004247A 2004-10-19 2005-10-19 Agentes de aglutinacion especifica a angiopoyetina-2. MX2007004247A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
MX2007004247A true MX2007004247A (es) 2007-06-12

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007004247A MX2007004247A (es) 2004-10-19 2005-10-19 Agentes de aglutinacion especifica a angiopoyetina-2.

Country Status (10)

Country Link
JP (2) JP2008520188A (enExample)
CN (1) CN101495513B (enExample)
BR (1) BRPI0518209A (enExample)
EA (1) EA011866B1 (enExample)
IL (1) IL182279A0 (enExample)
MA (1) MA29015B1 (enExample)
MX (1) MX2007004247A (enExample)
RU (2) RU2404992C2 (enExample)
SG (1) SG156668A1 (enExample)
ZA (1) ZA200704020B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
PT1292335E (pt) * 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2473970C (en) * 2001-10-12 2013-05-28 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
IL182279A0 (en) 2007-07-24
RU2007118670A (ru) 2008-12-27
BRPI0518209A (pt) 2008-11-04
SG156668A1 (en) 2009-11-26
EA200700876A1 (ru) 2007-10-26
RU2404992C2 (ru) 2010-11-27
ZA200704020B (en) 2008-06-25
CN101495513B (zh) 2014-08-06
CN101495513A (zh) 2009-07-29
RU2010132956A (ru) 2012-02-10
EA011866B1 (ru) 2009-06-30
JP2011207882A (ja) 2011-10-20
JP2008520188A (ja) 2008-06-19
MA29015B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
WO2003030833A3 (en) Angiopoietin-2 specific binding agents
MY156458A (en) Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
SG156668A1 (en) Angiopoietin-2 specific binding agents
LUC00025I1 (enExample)
SG166090A1 (en) Il-13 binding agents
WO2010017103A3 (en) Fully human anti-human nkg2d monoclonal antibodies
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
WO2012047583A3 (en) Antibodies binding human collagen ii
EA200400526A1 (ru) Агенты, специфически связывающиеся с человеческим ангиопоэтином-2
IL244803B (en) Human anti-beta antibodies and their use
PH12015501848A1 (en) Binding agents
EP1912674B8 (en) Bispecific single chain fv antibody molecules and methods of use thereof
TW200635946A (en) Binding proteins specific for human matriptase
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
WO2006029220A3 (en) Combination therapy with anti-ctla4 and anti-4-1bb antibodies
WO2006116319A3 (en) Reagents that bind ccx-ckr2
WO2007076465A3 (en) Cln248 antibody compositions and methods of use
TN2010000374A1 (en) Antibodies directed to angiopoietin -1 and angiopoietin-2 and use thereof

Legal Events

Date Code Title Description
FG Grant or registration